Homocysteine and Cognitive Function

Aron Troen; Irwin Rosenberg

doi:10.1055/s-2005-872406

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2005; 5(2): 209-214
DOI: 10.1055/s-2005-872406

Homocysteine and Cognitive Function

Aron Troen¹ , Irwin Rosenberg¹

¹Nutrition and Neurocognition Laboratory and Vitamin Metabolism and Aging Laboratory, The Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111

Abstract

ABSTRACT

The prevention and treatment of age-related cognitive impairment and dementia is one of the greatest and most elusive challenges of our time. The prevalence of dementia increases exponentially with age, as does the prevalence of those with micronutrient deficiency. Several studies have shown that elevated homocysteine is correlated with cognitive decline and with cerebral atrophy and that it predicts the subsequent development of dementia in cognitively intact middle-aged and elderly individuals. If elevated homocysteine promotes cognitive dysfunction, then lowering homocysteine by means of B-vitamin supplementation may protect cognitive function by arresting or slowing the disease process.

KEYWORDS

Homocysteine - cognitive function - dementia

Full Text

References

REFERENCES

1 Katzman R, Kawas C. The epidemiology of dementia and Alzheimer disease. In: Terry RD, Katzman R, Bick KL Alzheimer Disease New York; Rave Press 1994: 105-122
2 Smith A D. Homocysteine, B vitamins and cognitive deficit in the elderly. Am J Clin Nutr. 2002; 75 785-786
3 Beiser A, Au R, DeCarli C et al.. Higher levels of plasma homocysteine are associated with subsequent lower brain volume and poorer performance on tests of attention and concentration: the Framingham offspring study. The 8th International Conference on Alzheimer's Disease and Related Disorders Stockholm, Sweden; July 20-25, 2002
4 Seshadri S, Beiser A, Selhub J et al.. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002; 346 476-483
5 Selhub J, Bagley L C, Miller J, Rosenberg I H. B vitamins, homocyseine, and neurocognitive function in the elderly. Am J Clin Nutr. 2000; 71 614S-620S
6 Yoo J H, Chung C S, Kang S S. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke. 1998; 29 2478-2483
7 Bostom A G, Rosenberg I H, Silbershatz H et al.. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med. 1999; 131 352-355
8 Brattstrom L E, Hardevo J E, Hultverg B L. Moderate homocysteinemia-a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke. 1984; 15 1012-1016
9 Boushey C J, Beresford S AA, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274 1049-1057
10 Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy. Lancet. 1999; 353 1586-1587
11 Hogervorst E, Ribeiro H M, Molyneux A, Budge M, Smith A D. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol. 2002; 59 787-793
12 Clarke R, Smith A D, Jobst K A, Refsum H, Sutton L, Ueland P M. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998; 55 1449-1455
13 Moller J, Nielsen G M, Tvedegaard K C, Andersen N T, Jorgensen P E. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest. 2000; 60 491-499
14 Alfthan G, Pekkanen J, Jauhiainen M et al.. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994; 106 9-19
15 Fallon U B, Elwood P, Ben-Shlomo Y, Ubbink J B, Greenwood R, Smith G D. Homocysteine and ischaemic stroke in men: the Caerphilly study. J Epidemiol Community Health. 2001; 55 91-96
16 Verhoef P, Hennekens C H, Malinow M R, Kok F J, Willett W C, Stampfer M J. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994; 25 1924-1930
17 Bots M L, Launer L J, Lindemans J et al.. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med. 1999; 159 38-44
18 Perry I J, Refsum H, Morris R W, Ebrahim S B, Ueland P M, Shaper A G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995; 346 1395-1398
19 Ridker P M, Manson J E, Buring J E, Shih J, Matias M, Hennekens C H. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999; 281 1817-1821
20 Casas J, Bautista L, Smeeth L, Sharma P, Hingorani A. Homocysteine and stroke: evidence on a causal link from mendelian randomization. Lancet. 2005; 365 224-232
21 Joosten E, Lesaffre E, Riezler R et al.. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease?. J Gerontol A Biol Sci Med Sci. 1997; 52 M76-M79
22 McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry. 1998; 13 235-239
23 Miller J W, Green R, Mungas D M, Reed B R, Jagust W J. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology. 2002; 58 1471-1475
24 Luchsinger J A, Tang M X, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology. 2004; 62 1972-1976
25 Ravaglia G, Forti P, Maioli F et al.. Elevated plasma homocysteine levels in centenarians are not associated with cognitive impairment. Mech Ageing Dev. 2000; 121 251-261
26 Storey S G, Suryadevara V, Aronow W S, Ahn C. Association of plasma homocysteine in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. J Gerontol A Biol Sci Med Sci. 2003; 58 M1135-M1136
27 Religa D, Styczynska M, Peplonska B et al.. Homocysteine, apolipoprotein E and methylenetetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord. 2003; 16 64-70
28 Lehmann M, Gottfries C G, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord. 1999; 10 12-20
29 Leblhuber F, Walli J, Artner-Dworzak E et al.. Hyperhomocysteinemia in dementia. J Neural Transm. 2000; 107 1469-1474
30 Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine concentration relates to the severity but not to the duration of Alzheimer's disease. Int J Geriatr Psychiatry. 2004; 19 666-672
31 de la Torre J C. Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. Gerontology. 1997; 43 26-43
32 Kalaria R N, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999; 13 S115-S123
33 Moody D M, Brown W R, Challa V R, Ghazi-Birry H S, Reboussin D M. Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer’s disease. Ann N Y Acad Sci. 1997; 826 103-116
34 Morris J H. Vascular dementia. In: Esiri MM, Morris JH The Neuropathology of Dementia Cambridge; Cambridge University Press 1997: 137-173
35 O'Brien M D. Vascular dementia is underdiagnosed. Arch Neurol. 1988; 45 797-798
36 Nagy Z, Esiri M M, Jobst K A et al.. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol. 1997; 56 165-170
37 Pollak R D, Pollak A, Idelson M, Bejarano-Achache I, Doron D, Blumenfeld A. The C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and vascular dementia. J Am Geriatr Soc. 2000; 48 664-668
38 Fassbender K, Mielke O, Bertsch T, Nafe B, Fröschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy. Lancet. 1999; 353 1586-1587
39 Brookmeyer R, Curriero F C. Survival curve estimation with partial non-random exposure information. Stat Med. 2002; 21 2671-2683
40 Morris M S, Jacques P F, Rosenberg I H, Selhub J. Hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 2001; 73 927-933
41 Riggs K M, Spiro A r, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr. 1996; 63 306-314
42 Bell I R, Edman J S, Selhub J et al.. Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people. Acta Psychiatr Scand. 1992; 86 386-390
43 Budge M, Johnston C, Hogervorst E et al.. Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann N Y Acad Sci. 2000; 903 407-410
44 Duthie S J, Whalley L J, Collins A R, Leaper S, Berger K, Deary I J. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr. 2002; 75 908-913
45 Miller J W, Green R, Ramos M I et al.. Homocysteine and cognitive function in the Sacramento Area Latino Study on Aging. Am J Clin Nutr. 2003; 78 441-447
46 Kalmijn S, Launer L J, Lindemans J, Bots M L, Hofman A, Breteler M M. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol. 1999; 150 283-289
47 Teunissen C E, Blom A H, Van Boxtel M P et al.. Homocysteine: a marker for cognitive performance? A longitudinal follow-up study. J Nutr Health Aging. 2003; 7 153-159
48 McCaddon A, Hudson P, Davies G, Hughes A, Williams J H, Wilkinson C. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord. 2001; 12 309-313
49 Kado D, Karlamangla A, Huang M et al.. Homocysteine versus the vitamins folate, B6 and B12 as predictors of cognitive function and cognitive decline in older high functioning adults: MacArthur studies of successful aging. Am J Med. 2005; , In press
50 Clarke R, Joachim C, Esiri M et al.. Leukoaraiosis at presentation and disease progression during follow-up in histologically confirmed cases of dementia. Ann N Y Acad Sci. 2000; 903 497-500
51 Sachdev P. Homocysteine, cerebrovascular disease and brain atrophy. J Neurol Sci. 2004; 226 25-29
52 Scott T M, Tucker K L, Bhadelia A et al.. Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders. Am J Geriatr Psychiatry. 2004; 12 631-638
53 Vermeer S E, van Dijk E J, Koudstaal P J et al.. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol. 2002; 51 285-289
54 den Heijer T, Vermeer S E, Clarke R et al.. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain. 2003; 126 170-175
55 Prins N D, Den Heijer T, Hofman A et al.. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology. 2002; 59 1375-1380
56 Dufouil C, Alperovitch A, Ducros V, Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol. 2003; 53 214-221
57 Troen A M, Lutgens E, Smith D E, Rosenberg I H, Selhub J. The atherogenic effect of excess methionine intake. Proc Natl Acad Sci USA. 2003; 100 15089-15094

Aron TroenPh.D.

Nutrition and Neurocognition Laboratory and Vitamin Metabolism and Aging Laboratory

The Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts